Novartis targets 'critical mass' in $660M OTC drug buyout

Novartis is acquiring a package of North American over-the-counter drugs -- including Excedrin, No-Doz and Comtrex -- from Bristol-Myers Squibb for $660 million. The news quickly sparked cheers from analysts, who saw the buyout as a good move for the Swiss drug giant. Novartis, already one of the largest OTC manufacturers in the world, said the move would give it greater "critical mass" in the North American market. Novartis announced on Thursday that its net profit in the first six months of the year was up 12 percent.

- read this story from Xinhuanet for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.